First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
2d
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...
In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback